The FDA’s approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer.
On 1 May 2026, the United States Food and Drug Administration approved Veppanu (vepdegestrant) for adults with oestrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, and in doing so rewrote the rules of how oncology drugs can work. Veppanu breast cancer treatment is not simply a new drug. It is the first representative of an entirely new therapeutic class to receive regulatory approval anywhere in the world. As the first heterobifunctional protein degrader, or PROTAC (proteolysis-targeting chimera), to be cleared by the FDA, Veppanu signals a fundamental shift in the biology of targeted cancer therapy. The approval was granted for patients whose disease has progressed following at least one line of endocrine therapy, and it arrived ahead of the FDA’s assigned PDUFA review date of 5 June 2026.
Understanding ESR1 Mutations: Who Is Affected
Oestrogen receptor-positive, HER2-negative breast cancer accounts for the majority of all breast cancer diagnoses globally. For many patients, standard endocrine therapies such as aromatase inhibitors and CDK4/6 inhibitors are effective in the early stages of treatment.
ESR1 mutations are among the most common acquired resistance mechanisms in this setting. These genetic alterations in the oestrogen receptor 1 gene allow tumour cells to activate oestrogenic signalling even in the absence of oestrogen, rendering aromatase inhibitors largely ineffective. Critically, ESR1 mutations emerge in approximately 50% of patients after exposure to first-line endocrine therapy. For this substantial patient population, options at the second-line stage and beyond have historically been few and functionally limited. Veppanu breast cancer treatment was developed specifically to address this unmet need, offering a mechanism capable of overcoming ESR1-driven resistance where conventional agents cannot.
What Is a PROTAC and Why Does It Matter?
Standard treatments for oestrogen receptor-positive breast cancer, including aromatase inhibitors and selective oestrogen receptor degraders such as fulvestrant, work by blocking or partially dismantling the oestrogen receptor. As a PROTAC, vepdegestrant works differently. It recruits the intracellular ubiquitin-proteasome system to achieve targeted degradation of the ER protein, a distinct approach from selective ER degraders, which achieve only partial ER degradation and require intramuscular administration.
Unlike fulvestrant, vepdegestrant simultaneously binds to the ER and the E3 ubiquitin ligase, which then directly tags the ER for proteasomal degradation. Rather than merely blocking the receptor, Veppanu marks it for complete destruction inside the cell. This more efficient mechanism of ER elimination may explain the superior outcomes seen in ESR1-mutant disease, where tumours have evolved the ability to grow independently of oestrogen.
The VERITAC-2 Trial: What the Data Shows
FDA approval was based on the pivotal Phase 3 VERITAC-2 clinical trial, a global, randomised, open-label study enrolling 624 patients across 213 sites in 25 countries. Among the 270 patients with confirmed ESR1 mutations, vepdegestrant demonstrated a statistically significant improvement in progression-free survival, reducing the risk of disease progression or death by 43% compared to fulvestrant. Median PFS was 5.0 months in the vepdegestrant arm versus 2.1 months in the fulvestrant arm (hazard ratio 0.57; p-value 0.0001).
Enrolled patients were aged between 26 and 89, with a median age of 60; 99.5% were women. All had previously received both hormone therapy and a CDK4/6 inhibitor. In the overall trial population (including patients without ESR1 mutations), median PFS was 3.7 months versus 3.6 months for fulvestrant, a difference that did not reach statistical significance. This reinforces the importance of confirmed ESR1 mutation status to guide patient selection.
The most commonly reported adverse effects were generally low grade. Treatment-emergent events in at least 10% of patients included fatigue (27% with vepdegestrant versus 16% with fulvestrant), increased alanine aminotransferase levels (14% versus 10%), nausea (13% versus 9%), anaemia (12% versus 8%), and neutropenia (12% versus 5%). Only 3% of patients receiving vepdegestrant discontinued treatment due to adverse events. Labelled precautions include QTc prolongation and embryo-foetal toxicity. The VERITAC-2 results were published simultaneously in The New England Journal of Medicine and presented at the 2025 American Society of Clinical Oncology Annual Meeting.
What Clinicians Are Saying
Erika Hamilton, MD, principal investigator of VERITAC-2 and Chair of the Breast Cancer Research Programme at the Sarah Cannon Research Institute in Nashville, Tennessee, described the approval as filling a critical gap. “Patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer have had minimal second-line treatment options once standard therapies are no longer effective. The approval of vepdegestrant gives clinicians another tool in the breast cancer treatment arsenal and brings renewed hope to individuals who need additional options,” she said.
Komal Jhaveri, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center and a co-investigator in the VERITAC-2 trial, has spoken about the practical realities of access following approval. Jhaveri noted that patients should expect “a minimum [of] a few weeks to a couple of months” before they are able to successfully fill their first prescriptions, as the healthcare system and specialty pharmacy networks complete the necessary preparation. She has also emphasised that ESR1 mutation status is the key enrichment biomarker for therapeutic impact, and that biomarker testing should be prioritised in clinical practice to ensure the right patients are identified promptly.
Companion Diagnostic: Testing Before Treatment
Concurrent with the drug approval, the FDA authorised Guardant360 CDx as a companion diagnostic to identify eligible patients via testing. This liquid biopsy-based platform detects ESR1 mutations from a blood sample, allowing clinicians to confirm eligibility without invasive tissue sampling. For oncology teams, this reinforces the importance of timely biomarker testing as a prerequisite to prescribing Veppanu. The approved dosing regimen is 200 mg taken orally once daily with food.
Who Developed Veppanu and What Comes Next
Veppanu was discovered by Arvinas and jointly developed by Arvinas and Pfizer under a global collaboration announced in July 2021. Within days of the FDA approval, a significant commercial development followed. Arvinas and Pfizer entered into a licence agreement with Rigel Pharmaceuticals, granting Rigel exclusive global rights to develop, manufacture, and commercialise Veppanu. Rigel will be responsible for the US launch and will own global rights with the ability to sublicence to partners outside the US.
Under the terms of the agreement, Arvinas and Pfizer will receive an upfront payment of $70 million and an additional $15 million upon completion of defined development and manufacturing transition activities. They will also be eligible for up to $320 million in contingent payments based on future development, regulatory, and commercial milestones, as well as tiered royalties on worldwide net sales. The transaction is subject to antitrust clearance and is expected to close in mid-June 2026.
NCCN Guidelines Updated
Clinical recognition of Veppanu moved quickly beyond the regulatory level. On 8 May 2026, the National Comprehensive Cancer Network added vepdegestrant to the latest NCCN Clinical Practice Guidelines in Oncology for Breast Cancer as a Category 2A treatment option for patients with hormone receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy plus a CDK4/6 inhibitor. Category 2A designation reflects uniform consensus among NCCN panel members that the recommendation is appropriate based on available evidence.
A New Class in Oncology
The significance of the Veppanu approval reaches beyond breast cancer. As the first FDA-approved PROTAC for any indication, it clinically validates a scientific concept that has been developing for more than two decades. The PROTAC approach, in which a bifunctional molecule simultaneously engages a target protein and an E3 ubiquitin ligase to direct the target for destruction, offers a fundamentally different way of thinking about drug design. Where conventional inhibitors are limited by the presence of the target, degraders eliminate it entirely. That distinction matters for many proteins that have historically been considered ‘undruggable’, and the pharmaceutical industry is watching closely to see how broadly the approach can be applied.
For patients with Veppanu breast cancer eligibility, those with confirmed ESR1-mutated, ER-positive, HER2-negative advanced disease who have progressed on standard endocrine therapy, the arrival of an oral, once-daily option with a clearly defined efficacy signal in their specific molecular subtype is a meaningful clinical development. As overall survival data from VERITAC-2 continues to mature and Rigel moves forward with commercialisation, the full picture will become clearer. What is already clear is that the PROTAC era in oncology has begun, and Veppanu is its opening entry.
